Clinical Trials Logo

Vitiligo clinical trials

View clinical trials related to Vitiligo.

Filter by:

NCT ID: NCT03384459 Recruiting - Vitiligo Clinical Trials

Maintenance Therapy of 308-nm Excimer Laser Therapy in Patients With Vitiligo

Start date: November 18, 2017
Phase: N/A
Study type: Interventional

Although vitiligo is difficult to cure, recurrences are frequent after treatment, and many patients suffer from concerns about recurrence as well as disease. Psoriasis, another indication for ultraviolet radiation treatment, has been established that it can safely and effectively reduce the recurrence of psoriasis through monthly maintenance therapy. The aim of this study was to evaluate the efficacy of 308-nm excimer laser therapy for the prevention of relapse in vitiligo.

NCT ID: NCT03384342 Recruiting - Vitiligo Clinical Trials

Maintenance Therapy of Narrow-band UV-B Therapy in Patients With Vitiligo

Start date: November 18, 2017
Phase: N/A
Study type: Interventional

Although vitiligo is difficult to cure, recurrences are frequent after treatment, and many patients suffer from concerns about recurrence as well as disease. Psoriasis, another indication for ultraviolet radiation treatment, has been established that it can safely and effectively reduce the recurrence of psoriasis through monthly maintenance therapy. The aim of this study was to evaluate the efficacy of Narrow-band UV-B therapy for the prevention of relapse in vitiligo.

NCT ID: NCT03371758 Recruiting - Autophagy Clinical Trials

Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

Start date: January 2017
Phase: N/A
Study type: Interventional

The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.

NCT ID: NCT03365141 Recruiting - Vitiligo Clinical Trials

Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo

Start date: November 14, 2017
Phase: N/A
Study type: Interventional

A randomized split-body pilot study was planned to confirm efficacy of intralesiona triamcinolone injection in patients with vitiligo

NCT ID: NCT03358082 Recruiting - Vitiligo Clinical Trials

Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

Start date: October 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate the effectiveness of Tacrolimus 0.03% ointment monotherapy in patients with vitiligo. Patients will be treated for 6 months and followed for 3 months after treatment. All types of vitiligo will be included.

NCT ID: NCT03340155 Recruiting - Psoriasis Clinical Trials

Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases

BioUV2017
Start date: October 30, 2017
Phase: N/A
Study type: Interventional

The molecular mechanisms of action of photo(chemo)therapy in skin diseases are investigated in this study. The phototherapeutic modalities employed include UVB (ultraviolet B), UVA (ultraviolet A), PUVA (psoralen+UVA) and/or extracorporeal photochemotherapy (photopheresis). The study will address whether and how photo(chemo)therapy affects specific biologic pathways in different skin disorders and search for predictive biomarkers.

NCT ID: NCT03199664 Recruiting - Vitiligo Clinical Trials

Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo

Start date: September 1, 2017
Phase: Phase 4
Study type: Interventional

The study will compare the effectiveness of combined treatment with NB-UVB and tacrolimus versus NB-UVB alone . Patients will be treated for 6 months and followed up after 3 months .All types of vitiligo will be included except universal vitiligo.

NCT ID: NCT03013049 Recruiting - Vitiligo Clinical Trials

A Novel Surgical Method in the Treatment of Unstable Vitiligo

Start date: January 2016
Phase: N/A
Study type: Interventional

Vitiligo is a complex disease causing a selective, often progressive, loss of functioning melanocytes from epidermal basal layer resulting in white patches on the skin and occasionally mucosae. Worldwide prevalence of vitiligo is around 1% whereas in India it is around 3-4% ranging from 0.46% to 8.8%. Etiopathogenesis of vitiligo is multifactorial consisting of genetic, immunological and environmental factors. Environmental and genetic factors act in concert to destroy melanocytes. Reactive oxygen species (ROS) play important roles in vitiligo pathology,but the autoimmune pathogenesis has been proposed as one of the main causes of vitiligo. Surgical methods, mainly transplantation of non cultured epidermal cell suspension are effective treatment for stable vitiligo. Transplantation of autologous noncultured epidermal cell suspension and non-cultured dermal cell suspension in combination (a mode of cellular grafting technique) is a novel surgical method for the treatment of vitiligo. Cytotoxic CD8+ ( cluster of differentiation 8+) cells in vitiligo perilesions may dictate the fate of transplantation, and strategies against CD8+ T cell activation might be beneficial for patients undergoing melanocyte transplantation. Mesenchymal cells could inhibit T cell proliferation and induce T cell apoptosis. Bartsch first identified and characterized dermal mesenchymal cells (DMCs). They have a multi-lineage differentiation potential into adipocytes, osteocytes and chondrocytes.Vitiligo patients' autologous melanocytes transplantation efficiency may be predicted by perilesional skin-homing CD8+ T cell activities, and the immunoregulatory DMCs might be used as auxiliary agent to improve the efficacy. This pilot study is planned to compare transplantation of autologous noncultured epidermal cell suspension v/s its combination with non-cultured dermal cell suspension as a novel method in vitiligo surgery in stability of vitiligo with regards to extent of repigmentation, color matching of repigmented area, patient satisfaction and adverse events if any. This is the first study using transplantation of autologous noncultured epidermal cell suspension and non-cultured dermal cell suspension in combination as a new modality in vitiligo surgery.

NCT ID: NCT02962180 Recruiting - Vitiligo Clinical Trials

Transplantation of Basal Cell Layer Suspension Using Derma-rolling System in Vitiligo

Start date: March 2016
Phase: N/A
Study type: Interventional

Actually the methods for melanocyte delivery are invasive and often sophisticated. The dermarolling system with needles causing tiny microinjuries in the epidermis could offer a minimally invasive and painless method of melanocyte transplantation. The purpose of the study is to develop a new and simple method for transepidermally delivering keratinocytes and melanocytes into vitiligo skin.

NCT ID: NCT02925767 Recruiting - Vitiligo Clinical Trials

Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in Vitiligo

Start date: August 2016
Phase: N/A
Study type: Interventional

A randomized controlled non-inferiority trial based on split-body was planned to compare the efficacy of 308-nm excimer laser and 311-nm Ti:Sapphire laser in patients with vitiligo.